1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (494)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5599)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5599)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer
    Meeting Abstract

    Fu, X.; Pereira, R.; De Angelis, C.; Nanda, S.; Qin, L.; Veeraraghavan, J.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Nardone, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • ER pathway activity signature as a biomarker for endocrine agent GDC-9545
    Meeting Abstract

    Daemen, A.; Spoerke, J. M.; Zhou, W.; Guan, J.; Ingalla, E.; Young, A.; Hafner, M.; Aimi, J.; Chang, C. W.; Giltnane, J. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer
    Meeting Abstract

    De Angelis, C.; Cataldo, M. L.; Nardone, A.; Veeraraghavan, J.; Fu, X.; Nanda, S.; Qin, L.; Sethunath, V.; Pereira, R.; Weigelt, B.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer
    Meeting Abstract

    De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Jansen, V. M.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Pereira, R.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches
    Meeting Abstract

    Chandarlapaty, S.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Carter, G. C.; Sheffield, K. M.; Gossai, A.; Huang, Y. J.; Zhu, Y. E.; Bowman, L.; Smith, E. N.; Mathur, R.; Cohen, A. B.; Baxi, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Whole-exome and RNA-sequencing analyses of acinic cell carcinomas of the breast
    Meeting Abstract

    Beca, F.; Lee, S. S. K.; Pareja, F.; Da Cruz Paula, A.; Selenica, P.; Ferrando, L.; Wen, H. Y.; Zhang, H.; Guerini-Rocco, E.; Rakha, E. A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Ming, J.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save